CD133 Antigen as a Potential Marker of Melanoma Stem Cells:
Journal
Stem cells international
ISSN: 1687-966X
Titre abrégé: Stem Cells Int
Pays: United States
ID NLM: 101535822
Informations de publication
Date de publication:
2020
2020
Historique:
received:
25
06
2020
revised:
23
09
2020
accepted:
03
12
2020
entrez:
11
1
2021
pubmed:
12
1
2021
medline:
12
1
2021
Statut:
epublish
Résumé
Melanoma is the most dangerous type of skin cancer. Cancer stem cells (CSCs) are suspected to be responsible for the cancer recurrence and in the consequence for cancer therapy failure. CD133 is a potential marker for detection of melanoma CSCs. Experiments were performed on the B16-F10 mouse melanoma cell line. CD133+ cells were isolated using an immunomagnetic cell sorting technique. After isolation proliferative and clonogenic potential of CD133+, CD133- and CD133+/- were evaluated. The potential of CD133+ and CD133- cells for tumor induction was conducted on C57BL/6J mouse model. Three different cell quantities (100, 1000, 10000) were tested. Tumor morphology, number of mitoses, and tumor necrosis area were analyzed. Average 0.12% CD133+ cells were isolated. Compared to CD133- and unsorted CD133+/- cells, CD133+ cells were characterized by the higher proliferative and clonogenic potential. These properties were not confirmed
Identifiants
pubmed: 33424978
doi: 10.1155/2020/8810476
pmc: PMC7774302
doi:
Types de publication
Journal Article
Langues
eng
Pagination
8810476Informations de copyright
Copyright © 2020 Tomasz Kloskowski et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Cancers (Basel). 2019 Oct 03;11(10):
pubmed: 31623313
Eur Rev Med Pharmacol Sci. 2015 May;19(10):1821-8
pubmed: 26044226
J Clin Oncol. 1996 Jan;14(1):7-17
pubmed: 8558223
Am J Pathol. 2014 May;184(5):1256-62
pubmed: 24589338
Nature. 2010 Jul 1;466(7302):133-7
pubmed: 20596026
BMJ. 2017 Nov 30;359:j5174
pubmed: 29191943
Stem Cells Dev. 2009 Oct;18(8):1127-34
pubmed: 19409053
PLoS One. 2011;6(8):e23383
pubmed: 21826251
J Clin Oncol. 2008 Jun 10;26(17):2890-4
pubmed: 18539969
J Invest Dermatol. 2009 Sep;129(9):2109-12
pubmed: 19340009
Cancer Res. 2005 Oct 1;65(19):8944-50
pubmed: 16204067
Cancer Res. 2012 Oct 1;72(19):5111-8
pubmed: 22865455
Eur J Cancer. 2007 Mar;43(5):935-46
pubmed: 17320377
Nature. 2008 Dec 4;456(7222):593-8
pubmed: 19052619
Cells. 2019 Jun 21;8(6):
pubmed: 31234438
Int J Oncol. 2012 Nov;41(5):1570-6
pubmed: 22922842
Melanoma Res. 2011 Oct;21(5):405-16
pubmed: 21900792
Ann Surg Oncol. 2018 Mar;25(3):617-625
pubmed: 29299710
J Oncol. 2019 Jul 16;2019:6486173
pubmed: 31379943
Cancer Lett. 2010 Jun 1;292(1):17-23
pubmed: 19944522
Br J Dermatol. 2004 Feb;150(2):179-85
pubmed: 14996086
Int J Biol Markers. 2016 May 28;31(2):e118-25
pubmed: 27102864
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8
pubmed: 12629218
Oncology (Williston Park). 2014 Dec;28(12):1101-7, 1110
pubmed: 25510809
Nat Med. 2017 Oct 6;23(10):1124-1134
pubmed: 28985214
Semin Oncol. 2015 Apr;42 Suppl 1:S3-17
pubmed: 25839664
Nat Med. 1997 Jul;3(7):730-7
pubmed: 9212098
Clin Transl Med. 2018 Jul 9;7(1):18
pubmed: 29984391
Cell Mol Immunol. 2007 Dec;4(6):467-72
pubmed: 18163959
Cancer Lett. 2015 Feb 1;357(1):83-104
pubmed: 25449786
Cancer Lett. 2014 Feb 1;343(1):123-33
pubmed: 24080340
Br J Dermatol. 2012 Nov;167(5):1124-30
pubmed: 22759278
PLoS One. 2014 Feb 26;9(2):e89834
pubmed: 24587067
Cell. 2010 May 14;141(4):583-94
pubmed: 20478252
Oncogene. 2020 Aug;39(32):5468-5478
pubmed: 32616888
Cancer Cell Int. 2013 Aug 06;13(1):78
pubmed: 23915418
Blood. 1997 Dec 15;90(12):5002-12
pubmed: 9389720
Cell Stem Cell. 2015 Mar 5;16(3):225-38
pubmed: 25748930
PLoS One. 2014 May 05;9(5):e92596
pubmed: 24799129